Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PDL-1”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableUnknownNCT02758314
What this trial is testing

Evaluation of PD1 / PDL1 Expression on Blood Cells & Tumor Tissue, Their Role as a Prognostic Target in NSCLC Patients

Who this might be right for
Non-Small Cell Lung Cancer
Instituto Nacional de Cancerologia de Mexico 150
Not applicableLooking for participantsNCT07038928
What this trial is testing

TReatment Approaches and bIomarkers preValence in bladdEr Cancer in RuSsian Federation

Who this might be right for
Bladder Cancer
AstraZeneca 600
Large-scale testing (Phase 3)Looking for participantsNCT07111832
What this trial is testing

A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer

Who this might be right for
PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 400
Testing effectiveness (Phase 2)Looking for participantsNCT06099821
What this trial is testing

KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade

Who this might be right for
Digestive System Cancers
Peking University Cancer Hospital & Institute 39
Large-scale testing (Phase 3)Looking for participantsNCT06103864
What this trial is testing

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

Who this might be right for
Breast Cancer
AstraZeneca 625
Large-scale testing (Phase 3)Ended earlyNCT04786964
What this trial is testing

Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC

Who this might be right for
Metastatic Non-squamous Non Small Cell Lung Cancer
Checkpoint Therapeutics, Inc. 25
Early research (Phase 1)UnknownNCT05735028
What this trial is testing

The Efficacy and Safety of PD-1/PD-L1 Inhibitors Combined With Centipeda Minima (CM) in Lung Cancer

Who this might be right for
Lung Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine 8
Testing effectiveness (Phase 2)Study completedNCT02859454
What this trial is testing

Avelumab for People With Recurrent Respiratory Papillomatosis

Who this might be right for
Recurrent Respiratory PapillomatosisJuvenile Laryngeal PapillomaLaryngeal Papilloma, Recurrent+2 more
National Cancer Institute (NCI) 13
Testing effectiveness (Phase 2)Looking for participantsNCT05253131
What this trial is testing

Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas

Who this might be right for
MPNSTNF1Sarcoma
University of Alabama at Birmingham 41
Testing effectiveness (Phase 2)UnknownNCT05386056
What this trial is testing

Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma

Who this might be right for
Esophageal Squamous Cell Carcinoma
Peking University 54
Very early researchWithdrawnNCT04186988
What this trial is testing

[18F]-AraG for the Detection of T-Cell Activation in Advanced Non-small Cell Lung Cancer Patients Undergoing PD-1/PD-L1-Directed Therapy

Who this might be right for
Advanced Lung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8+6 more
University of California, Davis
Early research (Phase 1)Ended earlyNCT02784483
What this trial is testing

Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma

Who this might be right for
Asymptomatic Myeloma
Yale University 2
Not applicableUnknownNCT06607120
What this trial is testing

Prognosis Stratification for Advanced HCC Receiving TACE with PD-1/PD-L1 Inhibitors and Molecular Target Therapies

Who this might be right for
Hepatocellular Carcinoma
Zhongda Hospital 950
Large-scale testing (Phase 3)Active Not RecruitingNCT06635824
What this trial is testing

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

Who this might be right for
PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC
Genmab 191
Large-scale testing (Phase 3)Ended earlyNCT04969861
What this trial is testing

BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)

Who this might be right for
Metastatic Head and Neck CancerRecurrent Head and Neck Cancer
Nektar Therapeutics 1
Testing effectiveness (Phase 2)UnknownNCT03656094
What this trial is testing

Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors

Who this might be right for
Non-small Cell Lung Cancer Metastatic
Samsung Medical Center 98
Large-scale testing (Phase 3)Study completedNCT03898180
What this trial is testing

Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

Who this might be right for
Urothelial Carcinoma
Merck Sharp & Dohme LLC 505
Not applicableStudy completedNCT05129462
What this trial is testing

Consistency of PD-L1 Detecting Method Between E1L3N and 22C3 Monoclonal Antibodies in NSCLC Patients

Who this might be right for
Non Small Cell Lung Cancer
Hunan Province Tumor Hospital 52
Early research (Phase 1)Ended earlyNCT02936102
What this trial is testing

FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

Who this might be right for
Advanced Solid TumorsTriple Negative Breast CancerChordoma and Alveolar Soft Part Sarcoma
Novartis Pharmaceuticals 154
Testing effectiveness (Phase 2)UnknownNCT06195683
What this trial is testing

Serplulimab for Patients With Non-small Cell Lung Cancer (NSCLC) With TPS ≥ 50%: a Prospective, Single-center, Single-arm Phase 2 Study.

Who this might be right for
Non-small Cell Lung CancerPDL1 Gene Mutation
Zhejiang Cancer Hospital 23
Next Page